甲磺酸伊马替尼治疗慢性粒细胞白血病疗效观察

The observation of the curative effect of chronic myeloid leukemia patients treated with imatinib mesylate

目的观察甲磺酸伊马替尼（IM）治疗慢性粒细胞白血病（CML）慢性期（CP）及进展期的疗效。方法回顾性分析2009年1月～2013年12月我院采用IM治疗的60例CML患者临床资料,其中30例为进展期患者,30例为CP患者。结果进展期患者DA化疗后血液学完全缓解0例,部分缓解6例,未缓解24例,总有效率20%;行IM治疗后完全缓解13例,部分缓解6例,未缓解11例,总有效率63.3%,两者治疗有效率差异有统计学意义（χ^2=4.36,P〈0.05）。30例CP患者行IM治疗后完全缓解26例,部分缓解0例,未缓解4例,总有效率86.7%,进展期及CP组IM治疗有效率差异有统计学意义（χ^2=11.59,P〈0.05）;进展期患者中McyR及CmoR的患者分别为10例（33.3%）和6例（20%）;CP组分别为26例（86.7%）和24例（80%）;CP患者IM治疗后遗传学疗效较进展期好。结论 IM是各期CML的理想治疗方法,有效率高。血液学毒性是其主要副作用,其余反应较轻,患者耐受良好。

Objective To investigate the curative effect of the chronic myeloid leukemia（CML） patients treated with imatinib（IM） mesylate in chronic phase（CP） and advanced phase. Methods The clinical data of 60 cases treated with imatinib mesylate in our hospital selected from Jan 2009 to Dec 2013 were analysed retrospectively. Results 0 case had complete response in the 30 advanced phase treated by DA cosmetic treatment, 6 cases had the part response, 24 cases had no response, the efficient rate was 20%. 13 cases had complete significant response in the 30 advanced phase treated by IM, 6 cases had the part response,11 cases had no response, the efficient rate was 63.3%,there were significant differences between the two groups（ χ^2=4.36,P〈0.05）. 26 cases had complete response in the CP group treated by IM,4 cases had no response, the efficient rate was 86.7%, there were significant differences between CP and advanced phase treated by IM. The complete cytogenetic response and complete molecular genetic response was 33.3%,20% in the advanced phase and the CP was 86.7%,80%. CP group treated by IM had better genetics curative effect than advanced phase group. Conclusion IM is a good way to cure CML,it has high efficient. It＇s side-effect is toxicity blood system,other bad reaction is little, patient tolerance is better.